Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on developing cancer therapies, has announced a conference call and webcast scheduled for August 8th, 2024, at 2 PM PT / 5 PM ET. The call will discuss the company's financial results and pipeline update for the second quarter of 2024, ending June 30th. Investors can join via phone or access the live webcast and presentation slides on the Arcus Biosciences website. A replay will be available after the event.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie per il cancro, ha annunciato una conferenza telefonica e una diretta web in programma per l'8 agosto 2024, alle 14:00 PT / 17:00 ET. La chiamata discuterà i risultati finanziari e l'aggiornamento del pipeline per il secondo trimestre del 2024, che termina il 30 giugno. Gli investitori possono partecipare tramite telefono o accedere alla diretta web e alle diapositive di presentazione sul sito web di Arcus Biosciences. Una registrazione sarà disponibile dopo l'evento.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias contra el cáncer, ha anunciado una llamada de conferencia y una transmisión web programada para el 8 de agosto de 2024, a las 2 PM PT / 5 PM ET. La llamada discutirá los resultados financieros y la actualización de la cartera para el segundo trimestre de 2024, que finaliza el 30 de junio. Los inversores pueden unirse por teléfono o acceder a la transmisión en vivo y las diapositivas de presentación en el sitio web de Arcus Biosciences. Una repetición estará disponible después del evento.
Arcus Biosciences (NYSE:RCUS)는 암 치료제 개발에 중점을 둔 임상 단계의 생물 제약 회사로, 2024년 8월 8일 오후 2시 PT / 오후 5시 ET에 예정된 컨퍼런스 콜 및 웹캐스트를 발표했습니다. 이번 통화에서는 2024년 2분기 재무 결과 및 파이프라인 업데이트에 대해 논의할 예정이며, 6월 30일 기준입니다. 투자자들은 전화로 참여하거나 Arcus Biosciences 웹사이트에서 라이브 웹캐스트 및 발표 슬라이드에 액세스할 수 있습니다. 이벤트 후 재생이 가능합니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapeutiques contre le cancer, a annoncé une conférence téléphonique et un webinaire prévus pour le 8 août 2024, à 14h00 PT / 17h00 ET. L'appel portera sur les résultats financiers et la mise à jour du pipeline pour le deuxième trimestre de 2024, se terminant le 30 juin. Les investisseurs peuvent se joindre par téléphone ou accéder au webinaire en direct et aux diapositives de présentation sur le site Web d'Arcus Biosciences. Un replay sera disponible après l'événement.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Krebstherapien spezialisiert hat, hat eine Telefonkonferenz und ein Webcast für den 8. August 2024, um 14:00 PT / 17:00 ET angekündigt. In der Konferenz wird über die finanziellen Ergebnisse und das Pipeline-Update für das zweite Quartal 2024 gesprochen, das am 30. Juni endet. Investoren können telefonisch teilnehmen oder den Live-Webcast sowie die Präsentationsfolien auf der Website von Arcus Biosciences abrufen. Eine Wiederholung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 287576. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725633260/en/
Investor Inquiries
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
When is Arcus Biosciences (RCUS) hosting its Q2 2024 earnings call?
How can investors access Arcus Biosciences' (RCUS) Q2 2024 earnings call?
What will be discussed in Arcus Biosciences' (RCUS) Q2 2024 conference call?
Where can investors find Arcus Biosciences' (RCUS) Q2 2024 earnings presentation?
